Thyrocare Technologies Intrinsic Value
THYROCARE Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹434.40 | ₹347.52 - ₹521.28 | -6.4% | EPS: ₹36.20, Sector P/E: 12x |
| Book Value Method | asset | ₹103.21 | ₹92.89 - ₹113.53 | -77.8% | Book Value/Share: ₹103.21, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹139.17 | ₹125.25 - ₹153.09 | -70.0% | Revenue/Share: ₹166.04, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹336.11 | ₹302.50 - ₹369.72 | -27.5% | EBITDA: ₹300.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹463.33 | ₹370.66 - ₹556.00 | -0.1% | CF Growth: 13.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹231.68 | ₹208.51 - ₹254.85 | -50.1% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹298.29 | ₹268.46 - ₹328.12 | -35.7% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹579.62 | ₹521.66 - ₹637.58 | +24.9% | ROE: 35.1%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹206.42 | ₹185.78 - ₹227.06 | -55.5% | EPS: ₹36.20, BVPS: ₹103.21 |
Want to compare with current market value? Check THYROCARE share price latest .
Valuation Comparison Chart
THYROCARE Intrinsic Value Analysis
What is the intrinsic value of THYROCARE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Thyrocare Technologies (THYROCARE) is ₹298.29 (median value). With the current market price of ₹463.90, this represents a -35.7% variance from our estimated fair value.
The valuation range spans from ₹103.21 to ₹579.62, indicating ₹103.21 - ₹579.62.
Is THYROCARE undervalued or overvalued?
Based on our multi-method analysis, Thyrocare Technologies (THYROCARE) appears to be trading above calculated value by approximately 35.7%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 14.08 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.27 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 35.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 33.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.27x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Thyrocare Technologies
Additional stock information and data for THYROCARE
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹191 Cr | ₹165 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹168 Cr | ₹123 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹129 Cr | ₹110 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹113 Cr | ₹101 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹115 Cr | ₹91 Cr | Positive Free Cash Flow | 8/10 |